• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP

CYNATA THERAPEUTICS LIMITED

0.00% ! 22.0¢
Market Cap $49.70M  !

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
CYP 12/03/25 3 799
12/03/25 Last post  gavint66 Comments Created with Sketch.  3  Views Created with Sketch.  799 
CYP 10/03/25 21 5.6K
10/03/25 Last post  Artephius Comments Created with Sketch.  21  Views Created with Sketch.  5.6K 
CYP
CYP Price Target post MSB FDA approval.
3 4 5
07/03/25 267 70K
07/03/25 Last post  Pledge Comments Created with Sketch.  267  Views Created with Sketch.  70K 
CYP 28/02/25 1 623
28/02/25 Last post  bedger Comments Created with Sketch.  1  Views Created with Sketch.  623 
CYP
Why Cynata's GvHD Treatment Might Not Need a Phase Two Trial for FDA Approval
27/02/25 9 2.7K
27/02/25 Last post  gavint66 Comments Created with Sketch.  9  Views Created with Sketch.  2.7K 
CYP 27/02/25 2 691
27/02/25 Last post  Eqz Comments Created with Sketch.  2  Views Created with Sketch.  691 
CYP 26/02/25 12 3.0K
26/02/25 Last post  Pledge Comments Created with Sketch.  12  Views Created with Sketch.  3.0K 
CYP 20/02/25 0 289
20/02/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  289 

See All Discussions arrow Created with Sketch.

Timeline

Cynata Participating in Euroz Hartleys Investor Conference
12 Mar 08:53
 
Appendix 4D & Half-Year Financial Statements
27 Feb 15:04
 
Expiry of listed CYPOA Options
27 Feb 11:58
 
Appendix 3Y - Paul Wotton
20 Feb 15:22
 
Application for quotation of securities - CYP
20 Feb 15:17
 
Investor Webinar
06 Feb 08:56
 
View More arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
22.0¢
Change
0.000(0.00%)
Mkt cap ! $49.70M
Open High Low Value Volume
22.0¢ 22.5¢ 22.0¢ $47.55K 215.5K

Buyers (Bids)

No. Vol. Price($)
2 35000 21.5¢
 

Sellers (Offers)

Price($) Vol. No.
22.0¢ 97101 1
View Market Depth
Last trade - 15.16pm 14/03/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.